Abstract: A compound of formula (I) or an optical isomer thereof, and pharmaceutically acceptable salts, prodrugs, aquo-complexes or non-aqueous-solvent complexes thereof are provided. Experiments prove that, compared with a control compound MGL-3196, the compound of formula (I), which is obtained through specific substitution sites and specific substitution types, is higher in agonist activity to THR-beta and significantly improved in selectivity on THR-beta/THR-alpha. The compound can be used in preparing THR-beta agonist and drugs for treating adaption diseases (including dyslipidemia, hypercholesteremia, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease) applicable to the THR-beta agonist.

Abstract: A hyperspectral camera based on a continuously variable film filter and a coating method thereof can solve interference between partial bands of the hyperspectral camera based on the continuously variable film filter. The hyperspectral camera includes: a camera body and a detector chip, wherein a continuously variable film is coated on the detector chip; a semi-transmission half-cut filter is provided in front of the continuously variable film, and a distance between the semi-transmission half-cut filter and the continuously variable film is 0 mm. According to the present invention, the semi-transparent half-cut filter and the detector chip are integrated without any gap therebetween. As a result, optical interference caused by incident light sequentially passing through the semi-transparent half-cut filter and the detector chip is greatly reduced, which can reduce distortion of spectral signals, and finally satisfy wide-band application requirements which can be truly realized based on such technology.

Abstract: Provided in the present invention are a 1-[(pyridin-3-yl-sulfonyl)-1h-pyrrol-3-yl] methanamine derivative having the structure shown below in formula (I) and a pharmaceutical composition and use thereof. The 1-[(pyridin-3-yl-sulfonyl)-1h-pyrrol-3-yl] methanamine derivative provided in the present invention has good gastric acid secretion inhibitory activities and excellent pharmacodynamic properties, while having relatively low toxicity.

Abstract: A hyperspectral camera based on a continuously variable film filter and a coating method thereof can solve interference between partial bands of the hyperspectral camera based on the continuously variable film filter. The hyperspectral camera includes: a camera body and a detector chip, wherein a continuously variable film is coated on the detector chip; a semi-transmission half-cut filter is provided in front of the continuously variable film, and a distance between the semi-transmission half-cut filter and the continuously variable film is 0 mm. According to the present invention, the semi-transparent half-cut filter and the detector chip are integrated without any gap therebetween. As a result, optical interference caused by incident light sequentially passing through the semi-transparent half-cut filter and the detector chip is greatly reduced, which can reduce distortion of spectral signals, and finally satisfy wide-band application requirements which can be truly realized based on such technology.

Abstract: Provided in the present invention are a 1-[(pyridin-3-yl-sulfonyl)-1h-pyrrol-3-yl] methanamine derivative having the structure shown below in formula (I) and a pharmaceutical composition and use thereof. The 1-[(pyridin-3-yl-sulfonyl)-1h-pyrrol-3-yl] methanamine derivative provided in the present invention has good gastric acid secretion inhibitory activities and excellent pharmacodynamic properties, while having relatively low toxicity.

Abstract: A lens scanning mode hyperspectral imaging system and a rotor unmanned aerial vehicle include: an imaging lens, an imaging spectrometer and a surface array detector arranged in sequence and coaxial to a main optic axis, wherein the imaging spectrometer and the surface array detector are connected and mounted to each other; wherein the lens scanning mode hyperspectral imaging system further includes: a driving device for driving the imaging lens to translate relative to a plane where a slit of the imaging spectrometer is. The hyperspectral imaging system of the present invention overcomes the technical bias in the prior art that the imaging lens must be fixed, and the present invention provides relative motion between the target object and the imaging spectrometer by the lens scanning mode for imaging, which solves the image distortion problem of conventional hyperspectral imaging system using a slit scanning mode or a scanning mode.

Abstract: The present disclosure provides a deuterium substituted 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine compound with a structure represented by formula (I) or a derivative thereof, a pharmaceutical composition containing the compound or the derivative thereof, and an application of the compound or the derivative thereof in preparing drugs. The compound can reduce oxidative metabolism thereof, increase the drug concentration in blood and the effective bioavailability, so as to lower the dosage and reduce the toxicity and other side effects. The deuterium 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine compound and its derivative thereof provided by the present disclosure can be used to treat related diseases such as affective disorders, depression and anxiety.

Abstract: A lens scanning mode hyperspectral imaging system and a rotor unmanned aerial vehicle include: an imaging lens, an imaging spectrometer and a surface array detector arranged in sequence and coaxial to a main optic axis, wherein the imaging spectrometer and the surface array detector are connected and mounted to each other; wherein the lens scanning mode hyperspectral imaging system further includes: a driving device for driving the imaging lens to translate relative to a plane where a slit of the imaging spectrometer is. The hyperspectral imaging system of the present invention overcomes the technical bias in the prior art that the imaging lens must be fixed, and the present invention provides relative motion between the target object and the imaging spectrometer by the lens scanning mode for imaging, which solves the image distortion problem of conventional hyperspectral imaging system using a slit scanning mode or a scanning mode.

Abstract: The present disclosure provides a deuterium substituted 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine compound with a structure represented by formula (I) or a derivative thereof, a pharmaceutical composition containing the compound or the derivative thereof, and an application of the compound or the derivative thereof in preparing drugs. The compound can reduce oxidative metabolism thereof, increase the drug concentration in blood and the effective bioavailability, so as to lower the dosage and reduce the toxicity and other side effects. The deuterium 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine compound and its derivative thereof provided by the present disclosure can be used to treat related diseases such as affective disorders, depression and anxiety.

Abstract: The present invention discloses and claims five (5) novel, highly efficient synthetic routes for the total synthesis of enantiomerically-pure (i.e., 99%) 7-(2?-trimethylsilyl)ethyl camptothecin (BNP1350; Karenitecin; Cositecan). These aforementioned synthetic schemes are the first to disclose the total syntheses of 7-(2?-trimethylsilyl)ethyl camptothecin using a highly novel direct, non-linear and convergent synthetic strategy which involves annealing the key C7-(trimethylsilyl)ethyl side chain-bearing A ring key synthons to an enantiomerically-pure tricyclic pyridone; rather than through the conventional methodology which incorporates the C7-(trimethylsilyl)ethyl side chain as the final synthetic step on a totally synthesized camptothecin parent compound.

Abstract: The present invention discloses and claims five (5) novel, highly efficient synthetic routes for the total synthesis of enantiomerically-pure (i.e., 99%) 7-(2?-trimethylsilyl)ethyl camptothecin (BNP1350; Karenitecin; Cositecan). These aforementioned synthetic schemes are the first to disclose the total syntheses of 7-(2?-trimethylsilyl)ethyl camptothecin using a highly novel direct, non-linear and convergent synthetic strategy which involves annealing the key C7-(trimethylsilyl)ethyl side chain-bearing A ring key synthons to an enantiomerically-pure tricyclic pyridone; rather than through the conventional methodology which incorporates the C7-(trimethylsilyl)ethyl side chain as the final synthetic step on a totally synthesized camptothecin parent compound.

Abstract: The present invention discloses: (i) the novel germanium-containing camptothecin compound, 7[2?-trimethylgermanyl]ethyl-20(S) camptothecin, and pharmaceutically-acceptable salts thereof; (ii) methods of synthesis of said novel germanium-containing camptothecin compound, 7[2?-trimethylgermanyl]ethyl-20(S) camptothecin, and pharmaceutically-acceptable salts; (iii) pharmaceutically-acceptable formulations comprising said novel germanium-containing camptothecin compound, 7[2?-trimethylgermanyl]ethyl-20(S) camptothecin, and pharmaceutically-acceptable salts thereof; and (iv) methods of administration of said novel germanium-containing camptothecin compound, 7[2?-trimethylgermanyl]ethyl-20(S) camptothecin, and pharmaceutically-acceptable salts thereof to subjects in need thereof, including subjects with cancer.

Abstract: The present invention discloses: (i) two novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (ii) methods of synthesis of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (iii) pharmaceutically-acceptable formulations comprising said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents; and (iv) methods of administration of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof.

Abstract: The present invention discloses: (i) two novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (ii) methods of synthesis of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, and/or derivatives thereof; (iii) pharmaceutically-acceptable formulations comprising said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents; and (iv) methods of administration of said novel deuterated Karenitecin® analogs, pharmaceutically-acceptable salts, derivatives thereof; and/or, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof.

Abstract: Disclosed herein are novel platinum-based analogs possessing two nitrile substituent groups (bis-nitrile) covalently-bonded to the platinum. Also disclosed herein are the reaction schemes for the synthesis of said platinum complexes, as well as quantitative in vitro IC50 data.

Abstract: The novel C10-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).

Abstract: The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).

Abstract: The novel C10-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).

Abstract: The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).

Abstract: Disclosed herein are novel platinum-based analogs possessing two nitrile substituent groups (bis-nitrile) covalently-bonded to the platinum. Also disclosed herein are the reaction schemes for the synthesis of said platinum complexes, as well as quantitative in vitro IC50 data.